NEWS
PRESS RELEASE
ECGP will be at ISPOR Glasgow 2025!
Join us for a conversation on the impact of Comprehensive Genomic Profiling (CGP) for patients at the upcoming ISPOR Issue Panel. Genomic testing is essential for personalised treatment because it matches patients to the most effective treatments based on disease’s molecular profile. CGP tests hundreds of biomarkers in one assay, delivering broader and more precise diagnostics. There is a need for Europe to move beyond small, sequential gene panels toward broader, comprehensive testing that capture the full molecular landscape of cancer and guide treatment decisions more effectively. Yet access to CGP remains limited across Europe. Join us on the ISPOR Issue…
Keep readingECGP Webinar: Unlocking the untapped potential of Comprehensive Genomic Profiling (CGP)
Genomic testing enables more personalised treatment decisions by identifying a broader range of genetic alterations in a single test. Access to Comprehensive Genomic Profiling (CGP) across Europe remains highly fragmented, with significant disparities in reimbursement, infrastructure, and integration into cancer care pathways, resulting in many patients missing out on effective targeted therapies. On Wednesday, 9 July, the ECGP Coalition will gather panellists in a 1-hour session to discuss CGP in healthcare systems and the recently published ECGP recommendations developed by ECGP in collaboration with renowned independent experts and patient advocates within the Steering Group. What to Expect: What is CGP, its value, and its untapped potential ECGP…
Keep readingThe Untapped Potential of Comprehensive Genomic Profiling – ECGP Recommendations
In recent years, significant steps have been taken to improve patient access to Comprehensive Genomic Profiling (CGP) in Europe, however today the full benefits are not yet realised. Access to CGP in Europe is limited, with European cancer patients not having access to potentially life-changing targeted cancer treatments because current funding and reimbursement frameworks do not allow for routine testing for all relevant cancer mutations. To address this, the multistakeholder European Coalition for Comprehensive Genomic Profiling (ECGP), made up of patients, clinicians, pathologists and industry, is publishing recommendations describing the value of CGP, and strategies for decision-makers to improve patient…
Keep reading